Literaturangaben

Zeitschrift für Infektionstherapie 5.2023

Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie

STD in Deutschland: Wissensstand vs. Wirklichkeit
(Seite 50)

1.    Burg G. History of sexually transmitted infections (STI). G Ital Dermatol Venerol 2021; 147:329-340. PMID: 23007208.

2.    Bonkat G. Syphilis and Henry VIII: A disease writes world history. Urologe A 2018: 57:1433-143. PMID: 30350130.

3.    Franzen C. Syphilis in composers and musicians Mozart, Beethoven, Paganini, Schubert, Schumann, Smetana. Eur J Clin Microbiol Infect Dis 2008; 27:1151-1157. PMID: 18592279.

4.    Bogousslavsky J, Tatu L. Édouard Manet's tabes dorsalis: from painful ataxia to Phantom limb. Eur Neurol 2016; 76:75-84. PMID: 27434214.

5.    André C, Rios AR. Furious Frederich: Nietzsche's neurosyphilis diagnosis and new hypotheses. Arq Neuropsiquiatr 2015; 73:1041-1043. PMID: 26465288.

6.    Bremer V, Dudareva-Vizule S, Buder S, an der Heiden M, Jansen K. Sexually transmitted infections in Germany: The current epidemiological situation. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017; 60: 948-957. PMID: 28741188.

7.    Jansen K. Syphilis in Deutschland im Jahr 2019 – Neuer Höchststand von Infektionen. Epidem Bull 2020; 49:3-13.

8.    Rasokat H. Syphilis 2020 – Die Infektionszahlen steigen stetig. Gyn Geburtshilfe 2020; 25:38-44.

9.    Haar K. Sechs Jahre STD-Sentinel-Surveillance in Deutschland – Zahlen und Fakten. Epidem Bull 2010; 3:20-27.

10.    Matthiesen S, von Rüden U, Dekker A, Briken P, Cerwenka S, Fedorowicz C, Wiessner C. How good is the knowledge about sexually transmitted infections in Germany?: Results of the first nationwide representative German health and sexuality survey (GeSiD). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021; 64:1355-1363. PMID: 33881551. PMCID: PMC8550710.

11.    https://de.statista.com/statistik/daten/studie/712050/umfrage/umfrage-zum-verdacht-einer-ansteckung-mit-einer-sti-in-deutschland/

12.    Samkange-Zeeb F, Mikolajczyk RT, Zeeb H. Awareness and knowledge of sexually transmitted diseases among secondary school students in two German cities. J Community Health 2013; 38: 293-300. PMID: 23001541.

13.    Samkange-Zeeb F, Pöttgen S, Zeeb H. Higher risk perception of HIV than of chlamydia and HPV among secondary school students in two German cities. PLoS One 2013; 8:e61636. PMID: 23637872. PMCID: PMC3634836.

14.    Kranz J, Rosellen J, Grundl S, Steffens J. Wissenserhebung zum Thema Jungendgesundheit – Trippa, Süfillis und Sackratten. 63. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie (06/2017; Essen).

15.    Samkange-Zeeb FN, Spallek L, Zeeb H. Awareness and knowledge of sexually transmitted diseases (STDs) among school-going adolescents in Europe: a systematic review of published literature. BMC Public Health 2011; 11:727. PMID: 21943100.

16.    https://www.aerzteblatt.de/nachrichten/98003/Praevention-mit-Humor-Zottelige-Puppen-klaeren-Jugendliche-ueber-sexuell-uebertragbare-Infektionen-auf

17.    Schneidewind L. School-based prevention programmes for adolescents: HIV, sexually transmitted infections, and pregnancy. Urologe A 2018; 57:723-726. PMID: 29744555.

18.    Ilskens K, Wrona KJ, Dockweiler C, Fischer F. An evidence map on serious games in preventing sexually transmitted infections among adolescents: systematic review about outcome categories investigated in primary studies. JMIR Serious Games 2022; 10:e30526. PMID: 35107438. PMCID: PMC8851332.

19.    Lengen C, Jäger S, Kistemann T. The knowledge, education and behaviour of young people with regard to Chlamydia trachomatis in Aarhus, Denmark and Bonn, Germany: do prevention concepts matter? Soc Sci Med 2010; 70:1789-1798. PMID: 20307923.

Unkomplizierte Harnwegsinfektionen – auch ohne Antibiotika? Diagnostik und (nicht)-antibiotische Therapie in der Primärversorgung (Seite 51)

1.    Butler C. C. et al. Incidence, severity, help seeking, and management of uncomplicated urinary tract infection: a population-based survey. Br J Gen Pract 2015; 65(639):e702-7. doi: 10.3399/bjgp15X686965

2.    Knottnerus B. J. et al. Women with symptoms of uncomplicated urinary tract infection are often willing to delay antibiotic treatment: a prospective cohort study. BMC Fam Pract. 2013; 14:71. doi: 10.1186/1471-2296-14-71

3.    Bleidorn J. et al. Why do – or don´t – patients participate in a clinical trial? A qualitative study in German family medicine. GMS Ger Med Sci 2015; published online: Oct 14 2015; 13:Doc1. doi: 10.3205/000221

4.    Interdisziplinare S3 Leitlinie: Epidemiologie, Diagnostik,Therapie, Pravention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Langversion 1.1-2, 2017AWMF Registernummer: 043/044, http://www.awmf.org/uploads/tx_szleitlinien/043044l_S3_Harnwegsinfektionen.pdf

5.    Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM): Brennen beim Wasserlassen. 2018. https://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053-001_Brennen%20beim%20Wasserlassen/053-001l_Brennen%20Wasserlassen_Langversion_29-08-18.pdf

6.    Knottnerus B.J. et al. Toward a simple diagnostic index for acute uncomplicated urinary tract infections. Ann Fam Med. 2013; 11(5):442-51. doi: 10.1370/afm.1513

7.    Klingeberg A. et al. Antibiotic-Resistant E. coli in Uncomplicated Community-Acquired Urinary Tract Infection. Dtsch Arztebl Int. 2018; published online Jul 23;115(29-30):494-500. doi: 10.3238/arztebl.2018.0494

8.    Gágyor I. et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351:h6544.
doi: 10.1136/bmj.h6544

9.    Vik I. et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PloS Med 2018; published online May 15 2018; 15(5):e1002569.
doi: 10.1371/journal.pmed.1002569

10.    Kronenberg A. et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359:j4784. doi: 10.1136/bmj.j4784

11.    Kaußner Y. et al. Reducing antibiotic use in uncomplicated urinary tract infections in adult women: a systematic review and individual participant data meta-analysis. Clin Microbiol Infect. 2022; 28(12):1558-1566.
doi: 10.1016/j.cmi.2022.06.017

12.    Gágyor I. et al. Herbal treatment with Uva Ursi extract versus fosfomycin for women with uncomplicated urinary tract infection – a double-blind, randomised, controlled comparative effectiveness phase 4 trial (REGATTA). Clin Microbiol Infect. 2021; 27(10):1441-1447.
doi: 10.1016/j.cmi.2021.05.032

13.    Wagenlehner F.M. et al. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int. 2018; 101(3):327–36.
doi: 10.1159/000493368

14.    Cooper T.E. et al. D-mannose for preventing and treating urinary tract infections. Cochrane Database Syst Rev. 2022;8(8):CD013608.
doi: 10.1002/14651858.CD013608.pub2

Impfstoffe gegen das Respiratorische Synzytial-Virus (RSV) – ein Überblick (Seite 52)

1. Robert Koch Institut (RKI). Respiratorische Synzytial-Virus-Infektionen (RSV) – RKI-Ratgeber; Stand 06.02.2018. https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_RSV.html#doc2394298bodyText8 [13.09.2023]

2. Rodriguez-Fernandez, R. et al. Monoclonal antibodies for prevention of respiratory syncytial virus infection. Pediatr Infect Dis J 2021; 40(5S): S35-S39.
doi: 10.1097/INF.0000000000003121

3. Fachinformation Arexvy®  (Respiratorischer Synzytial-Virus (RSV)-Impfstoff (rekombinant, adjuvantiert)), GlaxoSmithKline GmbH & Co. KG, Stand 06/2023.

4. Wagner, R., Hildt, E. Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen. Bundesgesundheitsbl 2019; 62:462-471.
doi: 10.1007/s00103-019-02921-1

5. Papi, A. et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388(7):595-608. doi: 10.1056/NEJMoa2209604

6. GlaxoSmithKline (GSK). GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons. Press release; published online Jun 21, 2023. https://us.gsk.com/en-us/media/press-releases/gsk-shares-positive-data-for-arexvy-its-respiratory-syncytial-virus-rsv-older-adult-vaccine-indicating-protection-over-two-rsv-seasons/ [13.09.2023]

7. European Medicines Agency (EMA). First RSV vaccine to protect infants up to 6 months of age and older adults; published online Jul 21, 2023. https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-older-adults [13.09.2023]

8. Europäische Kommission. EU genehmigt ersten Impfstoff zum Schutz von Säuglingen vor RSV- Infektionen. Pressemitteilung; published online Aug 25, 2023. https://germany.representation.ec.europa.eu/news/eu-genehmigt-ersten-impfstoff-zum-schutz-von-sauglingen-vor-rsv-infektionen-2023-08-25_de [13.09.2023]

9. Full Prescribing Information. ABRYSVO^TM (Respiratory Syncytial Virus Vaccine). Pfizer, 08/2023.

10. Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med 2023; 388(16):1451-1464. doi: 10.1056/NEJMoa2216480

11. U.S. Food & Drug Administration (FDA). FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. Press Announcement; published online Aug 21, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants [13.09.2023]

12. Fachinformation Abrysvo® (Respiratorischer Synzytial-Virus (RSV)-Impfstoff (bivalent, rekombinant)). Pfizer, Stand 08/2023.

13. Walsh, E. E. et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388(16):1465-1477. doi: 10.1056/NEJMoa2213836

14. vfa. Die forschenden Pharma-Unternehmen. In Entwicklung: Impfstoffe und anderer Schutz vor RSV. published online Sep 6, 2023. https://www.vfa.de/de/arzneimittel-forschung/impfen/schutz-vor-rsv [13.09.2023]